Want to see PTN full AI Analyst Report?
PTN Stock Chart & Stats
$10.37
--
Market closed
$10.37
--
Day’s Range― - ―
52-Week Range$5.40 - $31.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)64.61K
Market Cap
$10.67M
Enterprise Value$35.04M
Total Cash (Recent Filing)$7.49M
Total Debt (Recent Filing)$223.68K
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.25
Shares Outstanding1,780,939
10 Day Avg. Volume29,515
30 Day Avg. Volume64,605
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.56
Price to Sales (P/S)2.31
P/FCF Ratio-2.25
Enterprise Value/Market Cap3.28
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-4.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$11.67M
Bulls Say, Bears Say
Bulls Say
MC4R PipelineA diversified MC4R pipeline gives Palatin several potential paths into rare obesity indications, reducing dependence on one asset. The programs are designed around efficacy, selectivity, tolerability and convenient dosing, which could support differentiated products if clinical development confirms the preclinical promise.
Preclinical EfficacyConsistent weight-loss and food-intake effects across both peptide series provide a credible scientific foundation for planned human studies. While preclinical results are not clinical proof, this breadth of activity supports continued development and may improve partnering potential around the obesity platform.
Collaboration RevenuePartnered-asset revenue demonstrates that Palatin can monetize its intellectual property and research programs beyond internal product sales. The Boehringer agreement also provides potential milestone and royalty economics, creating an avenue for non-dilutive funding and broader validation of selected assets.
Bears Say
Going-Concern Funding RiskInsufficient cash runway is a durable constraint on Palatin’s ability to execute its development plan. Required financing could delay clinical milestones, force reliance on equity or partnership capital, and reduce strategic flexibility if funding is unavailable or obtained on unfavorable terms.
Persistent Cash BurnOngoing operating cash burn means Palatin cannot currently fund its business from internally generated resources. Continued losses therefore translate directly into recurring capital needs, making execution dependent on financing, licensing proceeds or milestone receipts rather than a self-sustaining operating model.
MC4R Tolerability RiskNausea, vomiting and hyperpigmentation could limit adherence, dosing, labeling or commercial adoption of MC4R therapies intended for lifelong treatment. These class-wide tolerability issues create a lasting development risk even as Palatin seeks improved selectivity and alternative molecule designs.
Palatin Technologies News
PTN FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest stock price was $5.40 and its highest was $31.00 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $10.67M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is Nov 16, 2026 which is in 25 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on Sep 28, 2026. The company reported -$1.11 earnings per share for the quarter, beating the consensus estimate of -$1.2 by $0.09.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Overvalued.
Does Palatin Technologies pay dividends?
Palatin Technologies does not currently pay dividends.
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 1,780,939 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$1.11 in its last earnings report, beating expectations of -$1.2. Following the earnings report the stock price went down -5.102%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in PTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
PTN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong optimism about Palatin's technical progress, preclinical MC4R data, collaboration activity and planned clinical development. However, the positive outlook is materially offset by the explicit going-concern warning, the need for additional financing before development milestones can proceed, higher expected operating expenses and the prior toxicity issue in the oral program. Overall, the tone was cautiously optimistic but financially constrained.View all PTN earnings summariesTechnical Analysis
Ownership Overview
11.20% Insiders
1.96% Mutual Funds
0.84% Other Institutional Investors
84.66% Public Companies and
Individual Investors